Therapy Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | RMC-9805 |
| Synonyms | |
| Therapy Description |
RMC-9805 inhibits KRAS G12D, which potentially results in reduced downstream signaling and proliferation, induction of apoptosis, and decreased tumor growth (Cancer Res 2023;83(7_Suppl):Abstract nr 526). |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| RMC-9805 | RMC 9805|RMC9805 | KRAS G12D Inhibitor 25 | RMC-9805 inhibits KRAS G12D, which potentially results in reduced downstream signaling and proliferation, induction of apoptosis, and decreased tumor growth (Cancer Res 2023;83(7_Suppl):Abstract nr 526). |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06040541 | Phase I | RMC-9805 | Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors | Recruiting | USA | 0 |
| NCT06162221 | Phase Ib/II | Daraxonrasib + Pembrolizumab + RMC-6291 Cisplatin + Daraxonrasib + Pembrolizumab + Pemetrexed Disodium + RMC-6291 Carboplatin + Daraxonrasib + Pembrolizumab + Pemetrexed Disodium Daraxonrasib + Pembrolizumab Cisplatin + Daraxonrasib + Pembrolizumab + Pemetrexed Disodium RMC-9805 Cisplatin + Daraxonrasib + Pemetrexed Disodium + RMC-9805 Carboplatin + Daraxonrasib + Pemetrexed Disodium + RMC-9805 Carboplatin + Daraxonrasib + Pembrolizumab + Pemetrexed Disodium + RMC-6291 Daraxonrasib + Pembrolizumab + RMC-9805 | Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC | Recruiting | USA | NLD | ITA | GRC | FRA | ESP | DEU | AUS | 1 |
CKB BOOST